AbbVie Inc. (BCBA:ABBV)

Market Cap	542.58T
Revenue (ttm)	81.74T
Net Income (ttm)	3.22T
Shares Out	n/a
EPS (ttm)	1,809.89
PE Ratio	168.61
Forward PE	15.74
Dividend	544.57 (1.68%)
Ex-Dividend Date	Jan 16, 2026

Volume	825
Average Volume	1,353
Open	32,960
Previous Close	32,420
Day's Range	32,300 - 33,160
52-Week Range	18,750 - 38,540
Beta	n/a
RSI	41.41
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD